千红制药 (002550)
Changzhou Qianhong Bio-pharma Co.,Ltd
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 127980.00
- Circulating A-Shares(W): 94124.02
- Earnings Per Share(RMB): 0.3066
- Net Assets Per Share(RMB): 2.1494
- Operating Revenue(W RMB): 121501.50
- Total Profit(W RMB): 43779.87
- Net Profit Attributable to Parent(W RMB): 38322.63
- Net Profit Growth Rate(%): 23.79
- Weighted Return on Equity(%): 14.5000
- Operating Cash Flow Per Share(RMB): 0.2280
- Undistributed Profit Per Share(RMB): 0.9965
- Capital Reserve Per Share(RMB): 0.0324
2. Main Business
The main business covers:
- Drug production, contract production, wholesale, retail, import and export.
- Technology import/export and agency.
- Medical packaging material manufacturing.
- Primary agricultural product procurement.
- Technical services, development, consultation, exchange, transfer, and promotion.
- Information consulting services.
- Non-residential real estate leasing and housing leasing.
3. Company Basic Information
- Company Name: Changzhou Qianhong Biopharma Co., Ltd.
- Listing Date: 2011-02-18
- Industry: Pharmaceutical Manufacturing
- Address: No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province, China
- Website: www.qhsh.com.cn
- Company Profile: Changzhou Qianhong Biopharma Co., Ltd. was established through the overall change of Changzhou Qianhong Biopharma Co., Ltd. The company completed its industrial and commercial registration with the Changzhou Administration for Market Regulation in Jiangsu Province on March 15, 2008.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 4903.52 | 5.21 |
| 2 | Ping An Securities - Zhou Guanxin - Ping An Securities Xin Chuang No. 50 Single Asset Management Plan | Asset Management Plan | 1947.69 | 2.07 |
| 3 | CCB Fund - Zhao Renyi - CCB Xin Xiang No.1 Single Asset Management Plan | Asset Management Plan | 1400.00 | 1.49 |
| 4 | Bodo CSI 1000 Index Enhanced Securities Investment Fund Class A | Fund | 31.17 | 0.03 |
5. Concept Sectors
- Hepatitis Concept
- Innovative Drugs
- Synthetic Biology
- Employee Stock Ownership
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information